PerkinElmer and University of Copenhagen Announce Licensing Agreement for Important New Maternal Health Marker ADAM12.

BOSTON -- PerkinElmer

--Marker Has Strong Potential to Improve Prenatal Risk Assessment

--Provides Enhanced Detection of Chromosomal Abnormalities and Diseases of Late Pregnancy

PerkinElmer Inc. (NYSE: PKI), a leading provider in neonatal and prenatal screening has entered into a global licensing agreement with the University of Copenhagen in Copenhagen, Denmark, to develop assay kits for the biochemical marker ADAM12. ADAM12 has broad potential in maternal health screening as a marker for fetal chromosomal abnormalities as well as for intrauterine growth retardation (IUGR) and pre-eclampsia, both of which can result in, maternal, fetal and long-term complications if left undiagnosed.

The license agreement covers exclusivity in North America and co-exclusivity in Europe, Central and South America. Kits will be developed for the complete portfolio of PerkinElmer platforms, including AutoDELFIA, DELFIA(R) Xpress and other DELFIA(R) platforms.

"We continue to invest in the high growth markets of maternal health and are very excited about the potential of this marker for improving the performance of prenatal risk assessment," said Peter Coggins, Ph.D., president of PerkinElmer Life & Analytical Sciences. "The inclusion of ADAM12 with other existing biochemical markers in both the first and second trimester of pregnancy is expected to offer enhanced detection and reduced false positives, therefore decreasing the need for invasive diagnostic testing."

"The University of Copenhagen is very pleased to announce the agreement with PerkinElmer. Our technology transfer unit was established to make sure that the University's most promising research results are commercialized in collaboration with companies who will be able to bring them to the market in an efficient and responsible way," said Ralf Hemmingsen, dean at the Faculty of Health Sciences, University of Copenhagen. "The dialogue with PerkinElmer has been very constructive and we find it immensely encouraging that research performed in Copenhagen will form the basis of a product that can be of benefit to pregnant women."

"Pre-eclampsia and other hypertensive disorders of pregnancy are a leading global cause of maternal and infant illness and death," said Coggins. "An early marker for this condition will provide the opportunity to investigate potential treatments at the early stage of the disease process, enable early intervention and improve the quality of life."

A team consisting of Dr. Ulla Wewer at the University of Copenhagen, Dr. Michael Christiansen from Statens Serum Institut (SSI) and Dr. Kevin Spencer at the Harold Wood Hospital in England have done all of the groundwork and tested ADAM12 in several thousand samples from pregnant women to investigate its importance for prediction of chromosomal disorders.

ADAM12 also shows potential to provide an early indicator of IUGR and pre-eclampsia, for which there are no current screening mechanisms. Early studies at the University of Copenhagen, SSI and Harold Wood have shown that ADAM12 levels were reduced at 10-14 weeks in pregnancies that developed pre-eclampsia and were greatly reduced in those exhibiting both pre-eclampsia and low birth weight.

Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that relate to prospective events or developments, including, without limitation, all projections of future financial results, are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements. There are a number of important risk factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including, without limitation, economic and geopolitical forces that may limit any continued or expected economic or end market strengthening or recoveries, risks related to our failure to introduce new products in a timely manner, the impact of our debt on our cash flow and investment opportunities, our ability to comply with financial covenants contained in our credit agreements and debt instruments, cyclical downturns continuing to affect several of the industries into which we sell our products, our ability to adjust our operations to address unexpected changes, our ability to execute acquisitions and license technologies and successfully integrate acquired businesses and licensed technologies into our existing business, the loss of any of our licenses that may require us to stop selling products or lose competitive advantage, competition, regulatory compliance, regulatory changes, our failure to obtain and enforce intellectual property protection, our defense of third party claims of patent infringement and our ability to realize the full value of our intangible assets, as well as other factors which we describe under the caption "Forward-Looking Information and Factors Affecting Future Performance" in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q, each on file with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Industrial Sciences markets to improve the quality of life. The Company reported revenues of $1.7 billion in 2004, has 10,000 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.